drugset / Trial / NCT02899338

Pharmacokinetics and Safety of BI 695501

NCT02899338

Phase 1 Completed 162 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To characterize and compare the pharmacokinetics and to assess the safety of BI 695501 after single injection using either auto injector or prefilled syringe.

Timeline

Start
2016-09-21
Primary completion
2017-02-09
Completion
2017-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 695501 Monoclonal antibody Subcutaneous

Indications

No indication recorded.